Valuation : Voyageur Pharmaceuticals Ltd.

Market Cap 37.35M 26.97M 23.24M 21.84M 19.96M 2.55B 37.5M 258M 99.93M 1.31B 101M 99.13M 4.22B P/E 2024
-5.24x
P/E 2025 -7.5x
Enterprise Value 37.12M 26.8M 23.1M 21.71M 19.84M 2.53B 37.27M 256M 99.31M 1.3B 101M 98.52M 4.19B EV / Sales 2024
-
EV / Sales 2025 2,423,581,172x
Free-Float
93.07%
Yield 2024 *
-
Yield 2025 -
Aug. 10 Voyageur Pharmaceuticals Ltd. Advances Mueller Iodine Extraction Process with 99.8% Purity Results and Planned Field Pilot Testing CI
Jul. 24 Voyageur Pharmaceuticals Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2026 CI
Jun. 18 Voyageur Pharmaceuticals Evaluates Three Locations in the United States for Integrated Iodine and Barium Contrast Media Manufacturing Facility CI
Jun. 10 Voyageur Pharmaceuticals Ltd Submits Multi-Year Area-Based Exploration Permit Application for Bulk Sampling and Feasibility Support At Frances Creek Barite Project CI
Jun. 04 Voyageur Pharmaceuticals Ltd. announced that it has received CAD 5.005278 million in funding CI
Apr. 30 Voyageur Pharmaceuticals Ltd. announced that it expects to receive CAD 10 million in funding CI
Apr. 30 Voyageur Pharmaceuticals Ltd. cancelled the transaction announced on March 24, 2026 CI
Apr. 24 Voyageur Pharmaceuticals Ltd. Reports Earnings Results for the First Quarter Ended February 28, 2026 CI
Mar. 27 Voyageur Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended November 30, 2025 CI
Mar. 26 Voyageur Pharmaceuticals Ltd. Auditor Raises 'Going Concern' Doubt CI
Mar. 23 Voyageur Pharmaceuticals Ltd. announced that it expects to receive CAD 7.5 million in funding CI
Mar. 04 Voyageur Pharmaceuticals Ltd. Announces Independent Laboratory Test Results for Its Barium Sulfate Active Pharmaceutical Ingredient CI
Feb. 23 Voyageur Pharmaceuticals Announces Collaboration with Bayer Aktiengesellschaft CI
1 day+3.03%
1 month+30.77%
3 months+100.00%
6 months+13.33%
1 week 0.16
Extreme 0.16
0.17
1 month 0.14
Extreme 0.135
0.18
Current year 0.07
Extreme 0.07
0.19
1 year 0.07
Extreme 0.07
0.2
3 years 0.04
Extreme 0.035
0.36
5 years 0.04
Extreme 0.035
0.36
10 years 0.04
Extreme 0.035
0.36
Manager TitleAgeSince
Chief Executive Officer - 2019-06-30
Director of Finance/CFO - 2022-08-16
Chief Tech/Sci/R&D Officer - 2024-09-16
Director TitleAgeSince
Director/Board Member - 2017-12-05
Director/Board Member - 2019-06-30
Chairman - 2025-04-29
Date Insider Type Main position Quantity % Market Cap. Importance
3/16/26 Option 16,367 0.0092% -
3/16/26 Other 0 0% -
3/9/26 Option

Executive/Senior Manager

150,000 0.0840%
Change 5-day change 1-year change 3-year change Capi.($)
+3.03%0.00%0.00%+240.00% 27.09M
-0.88%-2.27%+55.78%+106.31% 1,034B
-1.15%+3.56%+54.62%+71.50% 671B
-1.44%-0.65%+21.05%+73.05% 460B
+0.14%-1.92%+32.47%+37.60% 353B
-1.33%+3.96%+25.71%+45.03% 309B
-1.15%-0.89%-1.67%+12.21% 255B
-1.55%+0.05%+54.04%+70.32% 240B
-0.88%+1.24%-18.03%-54.06% 207B
-0.15%+1.43%+33.64%+96.99% 188B
Average -0.47%+0.85%+25.76%+69.89% 371.68B
Weighted average by Cap. -0.79%+1.04%+37.27%+66.09%

Financials

2024 2025
Net sales - 0.01 0.01 0.01 0.01 0.01 0.8 0.01 0.08 0.03 0.41 0.03 0.03 1.32
Net income -1.71M -1.23M -1.06M -998K -912K -117M -1.71M -11.8M -4.57M -59.73M -4.63M -4.53M -193M -3.53M -2.55M -2.2M -2.07M -1.89M -241M -3.55M -24.41M -9.45M -124M -9.59M -9.38M -399M
Net Debt -113K -81.33K -70.09K -65.87K -60.19K -7.69M -113K -778K -301K -3.94M -306K -299K -12.71M -231K -166K -143K -135K -123K -15.74M -232K -1.59M -617K -8.07M -626K -612K -26.03M
Logo Voyageur Pharmaceuticals Ltd.
Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine active pharmaceutical ingredients (API) and imaging contrast agents for medical radiology. It focuses on vertically integrating the barium and iodine contrast markets. In addition, Voyageur is pursuing the development of new endo fullerene drugs. Its products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. At the core of its operations, the Company also owns a 100% interest in the Frances Creek Project, which boasts a mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.
Employees
-
Date Price Change Volume
26-09-04 CA$0.1700 +3.03% 186,600
26-09-03 CA$0.1650 -2.94% 40,722
26-09-02 CA$0.1700 +3.03% 129,180
26-09-01 CA$0.1650 -2.94% 182,739
26-08-31 CA$0.1700 0.00% 145,406

Annual profits - Rate of surprise